Skip to main content
. 2016 Sep 27;7(46):75571–75584. doi: 10.18632/oncotarget.12289

Figure 1. Effects of anakinra on MDA-MB-231 breast cancer dissemination and growth in bone.

Figure 1

6-week old BALB/c nude mice were administered 1mg/kg/day anakinra 3-days before or 7 days after intra-venous injection of MDA-MB-231-IV cells and culled 28 days after tumour cell injection. Protocol outline shown in a. b. Shows the number +/− SEM and photomicrographs of DiD labelled, non-proliferating, tumour cells in the trabecular area of the tibia. c. Shows mean +/− SEM from two separate experiments (n=8 mice/experiment) percentage of mice with tumours in their hind limbs on day 28 and ex vivo photographs of GFP expressing tumours in the left tibiae of mice from experiment 2. Mean tumour area +/− SEM and time until detection of tumour growth in bone are shown in panels d and e. * = p < 0.01 compared with placebo, ^ = P < 0.01 compared with placebo or treatment protocol.